Javlor (Vinflunine)

Vinflunine interferes with microtubule dynamics by binding to tubulin and preventing polymerisation. This disruption halts cell division at the G2/M checkpoint, leading to programmed cell death (apoptosis) of rapidly proliferating cancer cells. Its mechanism is distinct from older Vinca alkaloids, offering a novel antimitotic effect.

The specific dose of Javlor is determined by the prescribing oncologist based on individual patient factors such as body surface area, renal and hepatic function, and prior treatment history. The prescriber will calculate the appropriate amount and schedule for each infusion cycle.

The safety of Javlor in pregnancy and lactation has not been established. It is classified as having an unknown risk to the fetus, and use is generally avoided unless the potential therapeutic benefit justifies the potential risk. Breastfeeding mothers should discuss alternatives with their healthcare provider.

To request Javlor, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics), and necessary import documentation.

Javlor offers a microtubule‑targeting approach distinct from immunotherapies such as pembrolizumab or antibody‑drug conjugates like enfortumab vedotin. While immunotherapies activate the immune system, vinflunine directly disrupts cancer cell division. Choice of therapy depends on prior treatment exposure, patient health status, and physician assessment of efficacy versus safety.

Javlor must be stored refrigerated at 2‑8 °C. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution. If the product must be transported, maintain the cold‑chain using validated insulated containers and temperature monitors.

Javlor is given as an intravenous infusion. The vial is reconstituted with the appropriate diluent under aseptic conditions, then administered through a peripheral or central line over a prescribed period, usually ranging from 30 minutes to several hours, depending on the dosing schedule set by the clinician.

The most serious adverse events include severe neutropenia that can lead to life‑threatening infections, significant bleeding due to platelet suppression, cardiac toxicity such as arrhythmias, and rare but severe allergic reactions. Patients should be monitored closely for signs of infection, bleeding, and cardiac symptoms throughout treatment.

Javlor is contraindicated in patients with known hypersensitivity to vinflunine or other Vinca alkaloids. It should also be avoided in individuals with severe hepatic impairment, uncontrolled infections, or those who are pregnant unless the potential benefit outweighs the risk. Clinicians must evaluate each patient’s medical history before initiating therapy.